tirzepatide pubchem | C225H348N48O68 | CID 156588324 Tirzepatide 10mg — Dual Receptor

The ADA now recommends GLP1 RAs with proven benefit to slow CKD progression and reduce CV risk in people with type 2 diabetes

PlexusDx delivers prescription-strength tirzepatide oral therapy without insurance requirements, with pricing that stays flat regardless of dose adjustments

Clinical Effectiveness and Outcomes Weight Loss Efficacy SURMOUNT trials show significant long-term body-weight reductions: SURMOUNT-1 22.9% average weight reduction at 15 mg 94% reduced risk of progression to type 2 diabetes 99% remained diabetes-free NNT = 9[7][8] SURMOUNT-3 6.9% initial lifestyle-based loss + 21.1% additional with tirzepatide Total mean loss 26.6% Placebo regained 3.3%[7] SURMOUNT-4 20.9% loss during lead-in +5.5% with continuation vs +14.0% regain on placebo 89.5% maintained 80% of initial loss Total loss 25.3% vs 9.9% placebo[8] Comparative Efficacy Tirzepatide produces greater mean weight reduction than semaglutide in comparative trials[6]

100% natural formula

Third-party Tested and made in the USA in our own facility that is FDA registered and GMP certified

: ( )